T-cell acute lymphoblastic leukemia from miRNA perspective: Basic concepts, experimental approaches, and potential biomarkers

Drobna, Monika; Szarzyńska‐Zawadzka, Bronisława; Dawidowska, Małgorzata

doi:10.1016/j.blre.2018.04.003

Cited by 24 publications

(40 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the first systematic review and meta-analysis study of our knowledge to conduct a thorough analysis effect on T-ALL with causespecific events in patients suffering from T-cell Acute lymphoblastic leukemia. As mentioned earlier, previously published literature reviews 20,[55][56][57] have hypothesised the possibility of use of miRNA in the prognosis of T-ALL patients.…”

Section: Discussionmentioning

confidence: 92%

<p>The Significance of miRNAs as a Prognostic Biomarker for Survival Outcome in T Cell – Acute Lymphoblastic Leukemia Patients: A Systematic Review and Meta-Analysis</p>

Sabarimurugan¹,

Kumarasamy

Madhav

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose: T-cell acute lymphoblastic leukemia (T-ALL) affects lymphoid cells. Previous studies have reported that miRNAs play a significant role in TALL prognosis and have the potential to function as biomarkers in TALL. Therefore, this systematic review and metaanalysis study was designed to evaluate the overall prognostic impact of miRNAs in TALL patients. Methods: Eligible studies published between Jan 2010 and April 2018 were retrieved from online bibliographic databases based on multiple keywords to generate search strings. Metaanalysis was performed using the outcome measure, Hazard Ratio (HR). A survival analysis of all studies was conducted and a subsequent forest plot was generated to evaluate the pooled effect size, across all TALL patients. Subgroup analysis was conducted based on demographic characteristics and commonly represented miRNAs among the included studies. Results: A total of 17 studies were included for systematic review, among which 16 studies were eligible for meta-analysis, which, in total discussed 32 different miRNAs. The mean effect size of HR value was 0.929 (CI 0.878-0984), which indicates a decrease in risk of death by 7.1%. The analysis was based on the random effects model with the heterogeneity measure index (I 2) being 84.92%. The pooled effect size (HR) of upregulated and downregulated miRNA expressions on survival outcome in the TALL patient was 0.787 (CI 0.732-0.845) and 1.225 (CI 1.110-1.344) respectively. The subgroup analysis was performed based on demographic characteristics (age, gender, lactate dehydrogenase, WBC count) and expression of miR221 and miR46a. Conclusion: Our systematic review and meta-analysis findings suggest that the overall miRNA expression is potentially associated with a decreased likelihood of death in TALL patients. Although our findings are inconclusive, the results point toward miRNA expression allowing for prognostic evaluation of TALL patients.

show abstract

Section: Discussionmentioning

confidence: 92%

<p>The Significance of miRNAs as a Prognostic Biomarker for Survival Outcome in T Cell – Acute Lymphoblastic Leukemia Patients: A Systematic Review and Meta-Analysis</p>

Sabarimurugan¹,

Kumarasamy

Madhav

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Importantly, the same study highlights miR‐708 as a predictor of GC response and risk stratification 81 . Even if miRNAs can control cell metabolism for example GR biosynthesis and activation, 82 these studies do not provide a functional link between miRNAs, cell metabolism, and drug resistance and remain so far with a predictive character.…”

Section: Cell Metabolism In Callmentioning

confidence: 99%

Metabolic reprogramming in childhood acute lymphoblastic leukemia

Sbirkov

Burnusuzov

Sarafian

2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

The first observations of altered metabolism in malignant cells were made nearly 100 years ago and therapeutic strategies targeting cell metabolism have been in clinical use for several decades. In this review, we summarize our current understanding of cell metabolism dysregulation in childhood acute lymphoblastic leukemia (cALL). Reprogramming of cellular bioenergetic processes can be expected in the three distinct stages of cALL: at diagnosis, during standard chemotherapy, and in cases of relapse. Upregulation of glycolysis, dependency on anaplerotic energy sources, and activation of the electron transport chain have all been observed in cALL.While the current treatment strategies are tackling some of these aberrations, cALL cells are likely to be able to rewire their metabolism in order to escape therapy, which may contribute to a refractory disease and relapse. Finally, here we focus on novel therapeutic approaches emerging from our evolving understanding of the alterations of different metabolic networks in lymphoblasts. K E Y W O R D SBioenergetics, cALL, cell metabolism, therapy

show abstract

“…Precursor T-cell lymphoblastic lymphoma/leukemia instead arises from early T cell progenitors. It is a rapidly growing, aggressive disease (14, 15), occurring more frequently in late childhood, adolescence and young adults. T-ALL represents 10-15% of pediatric and 20-25% of adult cases of ALL in the western world and Japan.…”

Section: Introductionmentioning

confidence: 99%

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Ghione

Moskowitz

Paola

et al. 2018

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Purpose of review: novel immunotherapies such as checkpoint inhibitors, bispecific and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells. These are rare diseases with generally poor clinical outcomes. This review describes the rational and preliminary results of these approaches for people with T cell lymphoma and leukemia. Recent findings: for T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, either normal or neoplastic, can cause significant toxicity. A need to develop novel safe and effective immunotherapies for T cell neoplasms exists. Summary: In this review, we will discuss the rationale for immunotherapy of T cell leukemia and lymphoma and present the most recent therapeutic approaches.

show abstract

T-cell acute lymphoblastic leukemia from miRNA perspective: Basic concepts, experimental approaches, and potential biomarkers

Cited by 24 publications

References 154 publications

<p>The Significance of miRNAs as a Prognostic Biomarker for Survival Outcome in T Cell – Acute Lymphoblastic Leukemia Patients: A Systematic Review and Meta-Analysis</p>

<p>The Significance of miRNAs as a Prognostic Biomarker for Survival Outcome in T Cell – Acute Lymphoblastic Leukemia Patients: A Systematic Review and Meta-Analysis</p>

Metabolic reprogramming in childhood acute lymphoblastic leukemia

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Contact Info

Product

Resources

About